{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:24:09Z","timestamp":1791357849044,"version":"4.3.1"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1681\/asn.2014111139","type":"journal-article","created":{"date-parts":[[2015,10,22]],"date-time":"2015-10-22T22:29:06Z","timestamp":1445552946000},"page":"1234-1244","source":"Crossref","is-referenced-by-count":179,"title":["Four-Week Studies of Oral Hypoxia-Inducible Factor\u2013Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia"],"prefix":"10.1681","volume":"27","author":[{"given":"Louis","family":"Holdstock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy M.","family":"Meadowcroft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayma","family":"Maier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan M.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delyth","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjay","family":"Rastogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Zeig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Lepore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander R.","family":"Cobitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-29-20230208","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1093\/ndt\/gfn601","article-title":"Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease.","volume":"24","author":"Vaziri","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"R2-29-20230208","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2011111078","article-title":"Mechanisms of anemia in CKD.","volume":"23","author":"Babitt","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"R3-29-20230208","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3949\/ccjm.73.3.289","article-title":"Anemia in chronic kidney disease: Causes, diagnosis, treatment.","volume":"73","author":"Nurko","year":"2006","journal-title":"Cleve Clin J Med"},{"key":"R5-29-20230208","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1053\/j.ajkd.2014.01.416","article-title":"KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD.","volume":"63","author":"Inker","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"R6-29-20230208","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1093\/ndt\/gfq336","article-title":"Target haemoglobin to aim for with erythropoiesis-stimulating agents: A position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study.","volume":"25","author":"Locatelli","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"R7-29-20230208","first-page":"ii1","article-title":"Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure.","volume":"19","author":"Locatelli","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"R8-29-20230208","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1744-9987.2010.00836.x","article-title":"2008 Japanese Society for Dialysis Therapy: Guidelines for renal anemia in chronic kidney disease.","volume":"14","author":"Tsubakihara","year":"2010","journal-title":"Ther Apher Dial"},{"key":"R9-29-20230208","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/nrneph.2010.139","article-title":"Iron supplementation to treat anemia in patients with chronic kidney disease.","volume":"6","author":"Besarab","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"R11-29-20230208","doi-asserted-by":"crossref","first-page":"726","DOI":"10.2215\/CJN.04950908","article-title":"Erythropoietin therapy, hemoglobin targets, and quality of life in healthy hemodialysis patients: A randomized trial.","volume":"4","author":"Foley","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R12-29-20230208","first-page":"3297","article-title":"Managing dialysis patients who develop anemia caused by chronic kidney disease: Focus on peginesatide.","volume":"8","author":"Valliant","year":"2013","journal-title":"Int J Nanomedicine"},{"key":"R13-29-20230208","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease.","volume":"355","author":"Singh","year":"2006","journal-title":"N Engl J Med"},{"key":"R14-29-20230208","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa062276","article-title":"Normalization of hemoglobin level in patients with chronic kidney disease and anemia.","volume":"355","author":"Dr\u00fceke","year":"2006","journal-title":"N Engl J Med"},{"key":"R15-29-20230208","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/01.NEP.0000365949.63155.fa","article-title":"Lessons from TREAT: Lower hemoglobin target, avoid ESA if possible.","volume":"2","author":"Singh","year":"2009","journal-title":"Nephrol Times"},{"key":"R16-29-20230208","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N Engl J Med"},{"key":"R17-29-20230208","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/ki.2008.295","article-title":"Secondary analysis of the CHOIR trial epoetin-\u03b1 dose and achieved hemoglobin outcomes.","volume":"74","author":"Szczech","year":"2008","journal-title":"Kidney Int"},{"key":"R18-29-20230208","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1056\/NEJMoa1005109","article-title":"Erythropoietic response and outcomes in kidney disease and type 2 diabetes.","volume":"363","author":"Solomon","year":"2010","journal-title":"N Engl J Med"},{"key":"R19-29-20230208","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/cpdd.83","article-title":"Effect of food and gemfibrozil on the pharmacokinetics of the novel prolyl hydroxylase inhibitor GSK1278863.","volume":"3","author":"Johnson","year":"2013","journal-title":"Clin Pharmacol Drug Devel"},{"key":"R20-29-20230208","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1586\/17474086.2014.941349","article-title":"Anemia in chronic kidney disease patients: Treatment recommendations and emerging therapies.","volume":"7","author":"Del Vecchio","year":"2014","journal-title":"Expert Rev Hematol"},{"key":"R21-29-20230208","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.blre.2012.12.003","article-title":"Regulation of erythropoiesis by hypoxia-inducible factors.","volume":"27","author":"Haase","year":"2013","journal-title":"Blood Rev"},{"key":"R22-29-20230208","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1172\/JCI38499","article-title":"HIF-2alpha, but not HIF-1alpha, promotes iron absorption in mice.","volume":"119","author":"Mastrogiannaki","year":"2009","journal-title":"J Clin Invest"},{"key":"R23-29-20230208","doi-asserted-by":"crossref","first-page":"e25324","DOI":"10.1371\/journal.pone.0025324","article-title":"Hepcidin is involved in iron regulation in the ischemic brain.","volume":"6","author":"Ding","year":"2011","journal-title":"PLoS One"},{"key":"R24-29-20230208","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1525-139X.2008.00532.x","article-title":"The role of hepcidin in iron homeostasis and anemia in hemodialysis patients.","volume":"22","author":"Eleftheriadis","year":"2009","journal-title":"Semin Dial"},{"key":"R25-29-20230208","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1172\/JCI31370","article-title":"Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs).","volume":"117","author":"Peyssonnaux","year":"2007","journal-title":"J Clin Invest"},{"key":"R26-29-20230208","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1182\/blood-2007-02-073254","article-title":"HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques.","volume":"110","author":"Hsieh","year":"2007","journal-title":"Blood"},{"key":"R27-29-20230208","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1681\/ASN.2010010116","article-title":"Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD.","volume":"21","author":"Bernhardt","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"R28-29-20230208","first-page":"364684","article-title":"A possible novel anti-inflammatory mechanism for the pharmacological prolyl hydroxylase inhibitor 3,4-dihydroxybenzoate: Implications for use as a therapeutic for Parkinson\u2019s disease.","volume":"2012","author":"Chinta","year":"2012","journal-title":"Parkinsons Dis"},{"key":"R29-29-20230208","first-page":"731","article-title":"Prolyl hydroxylase inhibition attenuates hypoxia-induced microvascular inflammation via iNOS upregulation [Abstract].","volume":"22","author":"Tuley","year":"2008","journal-title":"FASEB J"},{"key":"R30-29-20230208","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1172\/JCI43273","article-title":"Prolyl hydroxylase 3 (PHD3) is essential for hypoxic regulation of neutrophilic inflammation in humans and mice.","volume":"121","author":"Walmsley","year":"2011","journal-title":"J Clin Invest"},{"key":"R31-29-20230208","first-page":"662A","article-title":"Induction of erythropoiesis in anemic patients by prolylhydroxylase inhibitor in a repeat dose, randomized placebo controlled trial [Abstract]","volume":"23","author":"Brigandi","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"R32-29-20230208","first-page":"196A","article-title":"Oral hypoxia-inducible factor prolyl hydroxylase inhibitor corrects anemia in nondialysis CKD patients without IV iron [Abstract]","volume":"22","author":"Besarab","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"R33-29-20230208","first-page":"203A","article-title":"Modulation of erythropoietin by prolyl hydroxylase inhibitor in a repeat dose, randomized placebo controlled trial [Abstract]","volume":"22","author":"Brigandi","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"R34-29-20230208","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.2215\/CJN.05671207","article-title":"Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis.","volume":"3","author":"McGowan","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"R35-29-20230208","first-page":"S92","article-title":"Steady-state pharmacokinetics of GSK1278863 and metabolites in subjects with normal and impaired renal function [Abstract]","volume":"97","author":"Yapa","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"R36-29-20230208","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/ki.1990.299","article-title":"Development of a new radioimmunoassay for erythropoietin using recombinant erythropoietin.","volume":"38","author":"Mason-Garcia","year":"1990","journal-title":"Kidney Int"},{"key":"R37-29-20230208","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1182\/blood-2010-08-299859","article-title":"Modulation of hepcidin production during hypoxia-induced erythropoiesis in humans in vivo: Data from the HIGHCARE project.","volume":"117","author":"Piperno","year":"2011","journal-title":"Blood"},{"key":"R38-29-20230208","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJM199808273390903","article-title":"The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.","volume":"339","author":"Besarab","year":"1998","journal-title":"N Engl J Med"},{"key":"R39-29-20230208","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1182\/blood-2007-08-106195","article-title":"Erythropoietin mediates hepcidin expression in hepatocytes through EPOR signaling and regulation of C\/EBPalpha.","volume":"111","author":"Pinto","year":"2008","journal-title":"Blood"},{"key":"R40-29-20230208","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/ki.2009.21","article-title":"Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease.","volume":"75","author":"Ashby","year":"2009","journal-title":"Kidney Int"},{"key":"R41-29-20230208","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1007\/s12185-012-1217-4","article-title":"Erythropoietin stimulation decreases hepcidin expression through hematopoietic activity on bone marrow cells in mice.","volume":"96","author":"Sasaki","year":"2012","journal-title":"Int J Hematol"},{"key":"R42-29-20230208","doi-asserted-by":"crossref","first-page":"4090","DOI":"10.1074\/jbc.M110.173096","article-title":"Regulation of type II transmembrane serine proteinase TMPRSS6 by hypoxia-inducible factors: New link between hypoxia signaling and iron homeostasis.","volume":"286","author":"Lakhal","year":"2011","journal-title":"J Biol Chem"},{"key":"R43-29-20230208","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3324\/haematol.2011.056119","article-title":"Hepatic hypoxia-inducible factor-2 down-regulates hepcidin expression in mice through an erythropoietin-mediated increase in erythropoiesis.","volume":"97","author":"Mastrogiannaki","year":"2012","journal-title":"Haematologica"},{"key":"R44-29-20230208","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1038\/jcbfm.2012.28","article-title":"Hypoxia-inducible factor prolyl hydroxylase inhibition: Robust new target or another big bust for stroke therapeutics?","volume":"32","author":"Karuppagounder","year":"2012","journal-title":"J Cereb Blood Flow Metab"},{"key":"R45-29-20230208","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0014-2999(99)00281-2","article-title":"Recombinant human erythropoietin stimulates vascular endothelial growth factor release by glomerular endothelial cells.","volume":"373","author":"Nitta","year":"1999","journal-title":"Eur J Pharmacol"},{"key":"R46-29-20230208","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nrc3627","article-title":"VEGF targets the tumour cell.","volume":"13","author":"Goel","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"R47-29-20230208","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/clpt.1989.121","article-title":"Time to stop counting the tablets?","volume":"46","author":"Pullar","year":"1989","journal-title":"Clin Pharmacol Ther"},{"key":"R48-29-20230208","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","article-title":"Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate.","volume":"145","author":"Levey","year":"2006","journal-title":"Ann Intern Med"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001751-201604000-00029","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:27:09Z","timestamp":1786130829000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001751-201604000-00029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2014111139","relation":{},"ISSN":["1046-6673"],"issn-type":[{"value":"1046-6673","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]}}}